<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:atom="http://www.w3.org/2005/Atom"  xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Ara in English - pharmaceuticals]]></title>
    <link><![CDATA[https://en.ara.cat/etiquetes/pharmaceuticals/]]></link>
    <description><![CDATA[Ara in English - pharmaceuticals]]></description>
    <language><![CDATA[es]]></language>
    <ttl>10</ttl>
    <atom:link href="https://en.ara.cat/rss-internal" rel="self" type="application/rss+xml"/>
    <item>
      <title><![CDATA["It is the biggest, most expensive and deadliest criminal conspiracy in the history of the United States"]]></title>
      <link><![CDATA[https://en.ara.cat/society/it-is-the-greatest-most-expensive-and-deadliest-criminal-conspiracy-in-the-history-of-the-united-states_128_5908540.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/cf1d1777-5585-4336-b204-41358969f942_16-9-aspect-ratio_default_0_x2194y1540.jpg" /></p><p>He was a correspondent for the <em>New York Times</em> at the White House and in New Delhi, and a reporter for the same newspaper covering the pharmaceutical sector. As a symbol of how he understands the profession, he has no photo on WhatsApp. He says that neither his name nor his face matters: only the stories he tells. Many of these stories have had significant consequences, such as the report that led to the Sunshine Act, the law that requires pharmaceutical companies to disclose payments to doctors. One of the big companies in the sector, Johnson and Johnson, became, in his own words, an “obsession.” He wanted to investigate their malpractice and ended up leaving the newspaper and current affairs to address it, in depth, in a book. The result is <em>No more tears</em>, translated into Spanish by Capitan Swing as <em>No llores más. Los oscuros secretos de Johnson & Johnson</em>. </p>]]></description>
      <dc:creator><![CDATA[Carla Turró]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/society/it-is-the-greatest-most-expensive-and-deadliest-criminal-conspiracy-in-the-history-of-the-united-states_128_5908540.html]]></guid>
      <pubDate><![CDATA[Thu, 12 Nov 2026 17:05:51 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/cf1d1777-5585-4336-b204-41358969f942_16-9-aspect-ratio_default_0_x2194y1540.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The journalist Gardiner Harris, author of the book 'No llores más, los oscuros secretos de Johnson & Johnson']]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/cf1d1777-5585-4336-b204-41358969f942_16-9-aspect-ratio_default_0_x2194y1540.jpg"/>
      <subtitle><![CDATA[journalist]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Almirall raises its profits by 36% up to September]]></title>
      <link><![CDATA[https://en.ara.cat/economy/almirall-raises-its-profits-by-36-up-to-september_1_5905035.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/26c1f3aa-79b1-4a57-8260-89d06a7a2764_16-9-aspect-ratio_default_0.jpg" /></p><p>The Catalan pharmaceutical company Almirall earned 53.3 million euros in the first nine months of 2026, 36.3% more than in the same period of the previous year, while its net sales increased by 8.3%, to 889.2 million, due to the good performance of the dermatology business in Europe. The company controlled by the Gallardo family published its accounts from January to September this Monday with the National Securities Market Commission (CNMV).</p>]]></description>
      <dc:creator><![CDATA[ARA]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/almirall-raises-its-profits-by-36-up-to-september_1_5905035.html]]></guid>
      <pubDate><![CDATA[Mon, 09 Nov 2026 11:37:31 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/26c1f3aa-79b1-4a57-8260-89d06a7a2764_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The facade of the headquarters of the Catalan pharmaceutical company Almirall on the Ronda General Mitre in Barcelona, in a file image.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/26c1f3aa-79b1-4a57-8260-89d06a7a2764_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The good evolution of the dermatological business boosts turnover and results]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Grifols earns 390 million until September, 28% more]]></title>
      <link><![CDATA[https://en.ara.cat/economy/grifols-earns-390-million-until-september-28-more_1_5897914.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/1baca7c3-482c-44ba-9aa6-6a9995e1ed5f_16-9-aspect-ratio_default_0.jpg" /></p><p>Grifols earned 162 million euros in the third quarter, 28% more than the previous year. The Catalan blood-derived products giant has been boosted by its biopharmaceutical business and increased its revenue in the period by 8.4% year-on-year at constant exchange rates, reaching 2.040 billion euros. With this result, according to what the multinational reported in a statement, the turnover for the first nine months of the year rose to 5.614 billion euros, 4.6% more than a year earlier. Profit between January and September, for its part, reached 390 million euros, 28.4% more. </p>]]></description>
      <dc:creator><![CDATA[ARA]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/grifols-earns-390-million-until-september-28-more_1_5897914.html]]></guid>
      <pubDate><![CDATA[Mon, 02 Nov 2026 17:57:23 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/1baca7c3-482c-44ba-9aa6-6a9995e1ed5f_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The headquarters of Grifols]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/1baca7c3-482c-44ba-9aa6-6a9995e1ed5f_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The Catalan pharmaceutical company announces a new dividend and raises the free cash flow to 298 million in the first nine months of the year]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Genetic wealth: a millionaire business that does not return to the countries of origin]]></title>
      <link><![CDATA[https://en.ara.cat/science-technology/genetic-wealth-millionaire-business-that-does-not-return-to-the-countries-of-origin_1_5897219.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/92a4173d-23f1-4e19-ad7c-7e14f80162cc_16-9-aspect-ratio_default_0_x1923y935.jpg" /></p><p>Digitization shook the music industry at the end of the nineties: the internet and MP3s allowed songs to circulate around the world without physical media, and this forced an adaptation of copyright and <em>royalties. </em>Now biodiversity is facing a similar challenge: with the arrival of Digital Sequence Information (DSI), the DNA and RNA sequences of plants, animals, and microorganisms can be consulted in open-access databases, without the need to physically travel to the place of origin. This is the case of the Madagascar periwinkle, a plant from which vincristine and vinblastine are derived, two cancer drugs with which it is now possible to innovate without having to obtain new samples of the plant, which makes scientific research cheaper and easier.</p>]]></description>
      <dc:creator><![CDATA[Lola Medina]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/science-technology/genetic-wealth-millionaire-business-that-does-not-return-to-the-countries-of-origin_1_5897219.html]]></guid>
      <pubDate><![CDATA[Mon, 02 Nov 2026 06:04:45 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/92a4173d-23f1-4e19-ad7c-7e14f80162cc_16-9-aspect-ratio_default_0_x1923y935.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Genetic representation of a plant.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/92a4173d-23f1-4e19-ad7c-7e14f80162cc_16-9-aspect-ratio_default_0_x1923y935.jpg"/>
      <subtitle><![CDATA[A United Nations initiative aspires to make large pharmaceutical companies pay for the commercial use of genetic data]]></subtitle>
    </item>
    <item>
      <title><![CDATA[The Catalan Esteve invests more than 70 million in a new plant in China]]></title>
      <link><![CDATA[https://en.ara.cat/economy/the-catalan-esteve-invests-more-than-70-million-in-new-plant-in-china_1_5885798.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/614724a3-b314-42f3-85a3-72a76fc4669c_16-9-aspect-ratio_default_0.jpg" /></p><p>Esteve CDMO, the Contract Development and Manufacturing Organization (CDMO) business of the Catalan pharmaceutical company, will invest 80 million dollars, equivalent to a little over 71 million euros, in a new production plant in China. This was announced in a statement this Wednesday, in which they detail that the move will serve to undertake the "relocation, expansion, and modernization" of its operations in the Asian giant.</p>]]></description>
      <dc:creator><![CDATA[Alberto Prieto]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/the-catalan-esteve-invests-more-than-70-million-in-new-plant-in-china_1_5885798.html]]></guid>
      <pubDate><![CDATA[Wed, 21 Oct 2026 11:27:59 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/614724a3-b314-42f3-85a3-72a76fc4669c_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Esteve's location in Shaoxing]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/614724a3-b314-42f3-85a3-72a76fc4669c_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The pharmaceutical company strengthens the business of manufacturing active ingredients for third parties in the Asian country]]></subtitle>
    </item>
    <item>
      <title><![CDATA[A laboratory that works like a bakery: Juanola lozenges celebrate 120 years]]></title>
      <link><![CDATA[https://en.ara.cat/business/laboratory-that-works-like-bakery-juanola-lozenges-celebrate-120-years_1_5868083.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/a81a81f4-45cf-4d6d-81f4-3a5b81979949_16-9-aspect-ratio_default_0_x1671y617.jpg" /></p><p>Surrounded by a strong smell of liquorice and equipped with gloves and hairnets, operators knead blocks of a tar-black color with an elasticity similar to bread dough. They place them on various trays to let them dry while, in another room, the pastes that have already completed their resting process are rolled and cut into small portions to then be packaged. The image, straddling the scenes of a bakery and those of a pharmaceutical laboratory, is the day-to-day life inside the Juanola lozenge factory, located in Sant Quirze del Vallès (Vallès Occidental). The legendary cough drop brand is celebrating 120 years and is doing so by preserving the essence of its product, while at the same time opening up to new business lines to reinvent itself for the future.</p>]]></description>
      <dc:creator><![CDATA[Albert Cadanet Vilà]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/business/laboratory-that-works-like-bakery-juanola-lozenges-celebrate-120-years_1_5868083.html]]></guid>
      <pubDate><![CDATA[Sat, 03 Oct 2026 06:01:45 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/a81a81f4-45cf-4d6d-81f4-3a5b81979949_16-9-aspect-ratio_default_0_x1671y617.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Employees of the Juanola lozenge factory working the liquorice-based dough that is used to make the final product.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/a81a81f4-45cf-4d6d-81f4-3a5b81979949_16-9-aspect-ratio_default_0_x1671y617.jpg"/>
      <subtitle><![CDATA[The renowned brand, based in Sant Quirze del Vallès, claims its origins while reinventing itself to face the future]]></subtitle>
    </item>
    <item>
      <title><![CDATA[The transfer of the production of the Salvat laboratories to Alcalá de Henares could affect up to 150 workers]]></title>
      <link><![CDATA[https://en.ara.cat/economy/the-transfer-of-the-production-of-the-salvat-laboratories-to-alcala-henares-could-affect-up-to-150-workers_1_5860327.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/a5099922-2116-463d-912c-cf17fa7a2126_16-9-aspect-ratio_default_0.jpg" /></p><p>The Catalan pharmaceutical company Salvat announced this Wednesday <a href="https://en.ara.cat/economy/salvat-laboratories-will-move-all-their-production-to-alcala-henares_1_5858653.html" >the intention to concentrate all its production capacity at the factory it has in Alcalá de Henares, in Madrid</a>. Conversely, this decision implies stopping production at the Esplugues de Llobregat plant. As reported by <em>La Vanguardia</em> and confirmed to ARA by union sources, the move will affect between 130 and 150 workers at the Catalan plant, who have for the moment been notified of a geographical mobility file. Currently, between 300 and 350 people work at the Salvat center in Esplugues de Llobregat.</p>]]></description>
      <dc:creator><![CDATA[Pol Casaponsa Sarabia]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/the-transfer-of-the-production-of-the-salvat-laboratories-to-alcala-henares-could-affect-up-to-150-workers_1_5860327.html]]></guid>
      <pubDate><![CDATA[Fri, 25 Sep 2026 08:53:27 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/a5099922-2116-463d-912c-cf17fa7a2126_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Salvat plant in Esplugues de Llobregat]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/a5099922-2116-463d-912c-cf17fa7a2126_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The move will impact five different departments, although the corporate headquarters will remain in Esplugues de Llobregat]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Salvat laboratories will move all their production from Esplugues to Alcalá de Henares]]></title>
      <link><![CDATA[https://en.ara.cat/economy/salvat-laboratories-will-move-all-their-production-to-alcala-henares_1_5858653.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/a5099922-2116-463d-912c-cf17fa7a2126_16-9-aspect-ratio_default_0.jpg" /></p><p>Significant step for Salvat laboratories. The Catalan family pharmaceutical company has decided to concentrate its entire production capacity at the factory it has in Alcalá de Henares, in Madrid. The move from the Esplugues de Llobregat plant will be progressive until 2030, according to its new strategic plan approved in July. The company is open to negotiating possibilities of geographical mobility for its staff "responsibly, maintaining dialogue with the legal representatives of the workers during the different phases of the transition".</p>]]></description>
      <dc:creator><![CDATA[Agustí Sala]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/salvat-laboratories-will-move-all-their-production-to-alcala-henares_1_5858653.html]]></guid>
      <pubDate><![CDATA[Wed, 23 Sep 2026 13:30:26 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/a5099922-2116-463d-912c-cf17fa7a2126_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Salvat plant in Esplugues de Llobregat]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/a5099922-2116-463d-912c-cf17fa7a2126_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The Catalan pharmaceutical company, which will negotiate a geographical mobility agreement with the workers, plans to carry out the move from now until 2030]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Grifols leverages its biopharmaceuticals division to raise profit to €227M in the first half]]></title>
      <link><![CDATA[https://en.ara.cat/economy/grifols-leverages-its-biopharmaceuticals-division-to-boost-profit-to-227m-in-the-first-half_1_5811312.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/1baca7c3-482c-44ba-9aa6-6a9995e1ed5f_16-9-aspect-ratio_default_0.jpg" /></p><p>Grifols earned 227 million euros during the first half of this year, 28.2% more than in the same period of the previous fiscal year. The Catalan multinational of plasma-derived medicines attributes the improvement, in large part, to the evolution of its biopharma division, its main source of income. According to the results published this Tuesday to the National Securities Market Commission (CNMV), the turnover of this area reached 3,148 million euros by June, 5.4% more year-on-year at constant exchange rates.</p>]]></description>
      <dc:creator><![CDATA[Albert Cadanet Vilà]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/grifols-leverages-its-biopharmaceuticals-division-to-boost-profit-to-227m-in-the-first-half_1_5811312.html]]></guid>
      <pubDate><![CDATA[Tue, 28 Jul 2026 16:35:15 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/1baca7c3-482c-44ba-9aa6-6a9995e1ed5f_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The headquarters of Grifols]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/1baca7c3-482c-44ba-9aa6-6a9995e1ed5f_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The Catalan multinational company has revenues exceeding €3,500M and consolidates the new organizational structure]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Ireland and its good treatment of multinationals destroy Europe's economic statistics]]></title>
      <link><![CDATA[https://en.ara.cat/economy/ireland-and-its-good-treatment-of-multinationals-destroy-europe-s-economic-statistics_1_5782550.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/570fec6e-da22-4e57-990d-0233ab5ab734_16-9-aspect-ratio_default_0.jpg" /></p><p>The large presence of multinationals – particularly, North American pharmaceutical companies – in Ireland's economy inflates the country's weight compared to its European Union partners, to the point that the adaptation of these companies to the tariffs imposed by the United States government has led the entire European economy to register negative growth rates in the first quarter of this year.</p>]]></description>
      <dc:creator><![CDATA[Leandre Ibar Penaba]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/ireland-and-its-good-treatment-of-multinationals-destroy-europe-s-economic-statistics_1_5782550.html]]></guid>
      <pubDate><![CDATA[Sun, 28 Jun 2026 06:00:42 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/570fec6e-da22-4e57-990d-0233ab5ab734_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Panoramic view Dublin in a stock image.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/570fec6e-da22-4e57-990d-0233ab5ab734_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The large weight on the island of large foreign corporations, especially pharmaceutical ones, leaves the EU's GDP in negative territory in the first quarter of this year]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Hipra exceeds for the first time 500 million euros in turnover]]></title>
      <link><![CDATA[https://en.ara.cat/economy/hipra-exceeds-for-the-first-time-500-million-euros-in-turnover_1_5777536.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/f2614f20-4463-46f1-bd4c-0353073ce26a_16-9-aspect-ratio_default_0.jpg" /></p><p>Hipra broke its business record in 2025. The Girona-based pharmaceutical company invoiced 516 million euros last year, its all-time high, and it is the first time it has exceeded 500 million in revenue in more than five decades of history. This represents an increase of 17% compared to the figures for 2024, in line with the company's aspirations to "grow above the market". On these sales, Hipra has achieved a profit close to 54 million euros, and has managed to reduce its debt to 145.5 million.</p>]]></description>
      <dc:creator><![CDATA[Alberto Prieto]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/hipra-exceeds-for-the-first-time-500-million-euros-in-turnover_1_5777536.html]]></guid>
      <pubDate><![CDATA[Tue, 23 Jun 2026 05:01:10 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/f2614f20-4463-46f1-bd4c-0353073ce26a_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Hipra has its headquarters in the town of Amer (in La Selva), where it researches and produces animal and also human vaccines.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/f2614f20-4463-46f1-bd4c-0353073ce26a_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The pharmaceutical company earns almost 54 million euros and exceeds 90 million in investment in 2025]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Grifols Egypt raises investment in the project to €460M]]></title>
      <link><![CDATA[https://en.ara.cat/economy/grifols-egypt-raises-investment-in-the-project-to-460-million_1_5766183.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/3518f121-cff9-49af-b6d1-47de7f6cac5e_16-9-aspect-ratio_default_0.jpg" /></p><p>The <a href="https://en.ara.cat/business/grifols-calm-two-years-after-the-stock-market-storm_1_5591877.html" >Grifols project in Egypt </a>is accelerating its development beyond expectations. The joint venture between the Catalan multinational and the Egyptian government, dedicated to achieving self-sufficiency in plasma derivatives, will invest an additional 180 million euros by 2029 to complete the project and substantially expand the network of donation centers. Initially, the plasma-derived medicines company and the African executive announced an allocation of 280 million euros. With the new growth plan, total financing will reach 460 million euros.</p>]]></description>
      <dc:creator><![CDATA[Alberto Prieto]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/grifols-egypt-raises-investment-in-the-project-to-460-million_1_5766183.html]]></guid>
      <pubDate><![CDATA[Fri, 12 Jun 2026 05:04:01 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/3518f121-cff9-49af-b6d1-47de7f6cac5e_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The 6th of October center of Grifols Egypt for Plasma Derivatives]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/3518f121-cff9-49af-b6d1-47de7f6cac5e_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The Catalan society with the Egyptian government seeks to double plasma donation centers until 2029 and assures that the project "will change the industry"]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Grifols lays the first stone of the new plant in Lliçà de Vall]]></title>
      <link><![CDATA[https://en.ara.cat/economy/grifols-places-the-first-stone-of-the-new-plant-in-llica-vall_1_5756894.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/1a3a5015-11a3-4e7f-ba7e-83cd848b5091_16-9-aspect-ratio_default_0.jpg" /></p><p>Grifols already has on the horizon the start of operations of the new production center <a href="https://en.ara.cat/economy/grifols-will-invest-160-million-in-new-plant-in-llica-vall_1_5445553.html" >in Lliçà de Vall (Vallès Oriental)</a>. The Catalan multinational in the plasma-derived medicines sector laid the first stone of the Vallès plant this Wednesday, which specializes in plasma fractionation and the production of derivatives. The new facilities will represent an investment of 160 million euros "in a first phase", as the company announced last summer, and will add approximately 400 new employees to the company's workforce, which already has about 4,700 employees in Spain. </p>]]></description>
      <dc:creator><![CDATA[Alberto Prieto]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/grifols-places-the-first-stone-of-the-new-plant-in-llica-vall_1_5756894.html]]></guid>
      <pubDate><![CDATA[Wed, 03 Jun 2026 11:07:32 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/1a3a5015-11a3-4e7f-ba7e-83cd848b5091_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Image of the laying of the first stone of the plant.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/1a3a5015-11a3-4e7f-ba7e-83cd848b5091_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The installation represents an investment of 160 million euros and will be operational in 2030]]></subtitle>
    </item>
    <item>
      <title><![CDATA[AstraZeneca warns of the loss of competitiveness of the European pharmaceutical sector]]></title>
      <link><![CDATA[https://en.ara.cat/economy/astrazeneca-warns-of-the-loss-of-competitiveness-of-the-european-pharmaceutical-sector_1_5756733.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/a615f330-e666-4ba1-9443-1efea927871e_16-9-aspect-ratio_default_0.jpg" /></p><p>The European pharmaceutical sector is losing competitiveness compared to the US and China. This was warned by the president of AstraZeneca in Spain, Laura Colón, during a round table within the framework of the Annual Meeting of the Cercle d'Economia, in Barcelona. This situation, influenced by issues such as excessive regulation and bureaucracy, is combined with the lengthening of life expectancy which, in large part, is due to new drugs. "We must ensure that governments realize the value of drugs and that they are not just a cost," she warned.</p>]]></description>
      <dc:creator><![CDATA[Agustí Sala]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/astrazeneca-warns-of-the-loss-of-competitiveness-of-the-european-pharmaceutical-sector_1_5756733.html]]></guid>
      <pubDate><![CDATA[Wed, 03 Jun 2026 09:22:22 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/a615f330-e666-4ba1-9443-1efea927871e_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Laura Colón, president of AstraZeneca Spain at the Annual Meeting of the Cercle d'Economia]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/a615f330-e666-4ba1-9443-1efea927871e_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The president of the company in Spain attributes the loss of competitiveness to over-regulation and excess bureaucracy]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Grifols closes 29 plasma donation centers in the United States]]></title>
      <link><![CDATA[https://en.ara.cat/economy/grifols-closes-29-plasma-donation-centers-in-the-united-states_1_5717365.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/48d43b13-4920-497e-abb3-78b9c8e45eea_16-9-aspect-ratio_default_0.jpg" /></p><p>The Catalan multinational pharmaceutical company Grifols will close 29 plasma donation centers in the United States, where it is the main operator with more than 300 centers. In a statement this Friday, it framed the decision within "a broader and ongoing strategy to improve long-term productivity, efficiency, and sustainability" of its network in the country.</p>]]></description>
      <dc:creator><![CDATA[Laura Casserres Capdevila]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/grifols-closes-29-plasma-donation-centers-in-the-united-states_1_5717365.html]]></guid>
      <pubDate><![CDATA[Fri, 24 Apr 2026 09:33:28 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/48d43b13-4920-497e-abb3-78b9c8e45eea_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Image of a Grifols laboratory where plasma is processed.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/48d43b13-4920-497e-abb3-78b9c8e45eea_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The EMA has approved the use of plasma from Egypt, where Grifols has a platform]]></subtitle>
    </item>
    <item>
      <title><![CDATA["This year Salvat will launch a drug in the US and another in China"]]></title>
      <link><![CDATA[https://en.ara.cat/business/this-year-salvat-will-launch-drug-in-the-us-and-another-in-china_128_5698117.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/6723e91a-dbd2-4448-b36f-fd276de56c24_16-9-aspect-ratio_default_0.jpg" /></p><p>Jordi Muntañola (Barcelona, 1978) has been the CEO of Salvat laboratories for a year. This molecular biologist from Esteve, who also held positions of responsibility at the Werfen group, has placed Salvat in the club of 100 million in turnover 12 months after initiating a major transformation to enhance the values and characteristics of a family-owned pharmaceutical company with over 70 years of history; a portfolio of its own products, with brands like the antiseptic Cristalmina, and a foundation to which it dedicates a portion of its profits. And, moreover, with great prospects, with the acceleration of the third-party production business and the launch during the first half of this year of a new product in the USA, with the prospect of marketing another next year and another in China. Always accompanied by a local partner, the formula it uses for internationalization, which has led it to be present in more than 60 countries. And without ruling out possible acquisitions, a path that the company may incorporate into the 2027-2030 strategic plan, which it expects to have ready this summer.</p>]]></description>
      <dc:creator><![CDATA[Agustí Sala]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/business/this-year-salvat-will-launch-drug-in-the-us-and-another-in-china_128_5698117.html]]></guid>
      <pubDate><![CDATA[Sat, 04 Apr 2026 06:03:15 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/6723e91a-dbd2-4448-b36f-fd276de56c24_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Jordi Muntañola at Salvat facilities in Esplugues del Lobregat]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/6723e91a-dbd2-4448-b36f-fd276de56c24_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[Chief Executive Officer of the pharmaceutical company Salvat]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Isdin will install a large logistics 'hub' in Martorelles]]></title>
      <link><![CDATA[https://en.ara.cat/economy/isdin-will-install-large-logistics-hub-in-martorelles_1_5692078.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/2d99dbec-8e5b-4a47-8577-202f6815b4c8_16-9-aspect-ratio_default_0.png" /></p><p>The Catalan company Isdin –specializing in dermatology and photoprotection– will establish the largest logistics facility in the company's history in Martorelles (Vallès Oriental). Specifically, they will build a <em>hub</em> of approximately 22,000 square meters with the aim of supporting the company's international growth. In a statement, Isdin assured this Friday that the new facilities will centralize a "very significant" part of the company's logistics operations, reinforcing Barcelona's role as the "nerve center of its global logistics".</p>]]></description>
      <dc:creator><![CDATA[ARA]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/isdin-will-install-large-logistics-hub-in-martorelles_1_5692078.html]]></guid>
      <pubDate><![CDATA[Fri, 27 Mar 2026 17:29:07 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/2d99dbec-8e5b-4a47-8577-202f6815b4c8_16-9-aspect-ratio_default_0.png" type="image/jpeg"/>
      <media:title><![CDATA[Recreation of the future Isdin plant in Martorelles.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/2d99dbec-8e5b-4a47-8577-202f6815b4c8_16-9-aspect-ratio_default_0.png"/>
      <subtitle><![CDATA[The enclosure in Vallès Oriental will be about 22,000 square meters]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Grifols is expanding its business model in the US, similar to Zara's.]]></title>
      <link><![CDATA[https://en.ara.cat/economy/grifols-is-expanding-its-business-model-in-the-us-similar-to-zara-s_1_5689879.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/d48f592b-91df-45f8-8014-e3ed77611b3b_16-9-aspect-ratio_default_0.jpg" /></p><p>Grifols is deepening its commitment to full integration and self-sufficiency in plasma production to avoid importing it to countries where blood donations are paid for. One instrument to reinforce this commitment will be <a href="https://en.ara.cat/economy/grifols-will-float-its-us-biopharma-business-the-stock-market_25_5688983.html">the initial public offering with a portion of the capital of the Biopharma division in the United States</a>The company has decided to take this step, announced Tuesday night to the Spanish National Securities Market Commission (CNMV), to strengthen its model in the US. This approach encompasses the entire value chain, from plasma collection to manufacturing, logistics, analysis, and distribution of blood products, comparable to the vertical integration of the Inditex-Zara model. According to market sources, the total value of the business to be listed is between €23.7 billion and €27.7 billion, between 13 and 15 times earnings before interest, taxes, depreciation, and amortization (EBITDA), and could substantially reduce Grifols' debt, which currently stands at €0. The company intends to carry out the operation through an initial public offering (IPO) for a minority stake, which, according to Bloomberg, could raise around €6 billion if 20% of the shares are offered. The company's shares, which had risen more than 8% in early trading, finished 1.36% higher on the Spanish market, reaching €8.96.</p>]]></description>
      <dc:creator><![CDATA[Agustí Sala]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/grifols-is-expanding-its-business-model-in-the-us-similar-to-zara-s_1_5689879.html]]></guid>
      <pubDate><![CDATA[Wed, 25 Mar 2026 18:57:23 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/d48f592b-91df-45f8-8014-e3ed77611b3b_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Grifols shareholders' meeting last year.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/d48f592b-91df-45f8-8014-e3ed77611b3b_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The company, which will float its US Biopharma business, valued at up to $27 billion, covers the entire value chain for producing blood products.]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Reig Jofre's profit falls by 52% to 4.99 million euros]]></title>
      <link><![CDATA[https://en.ara.cat/economy/reig-jofre-s-profit-falls-by-52-to-4-99-million-euros_1_5662672.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/4516c048-8000-407f-ad9c-5f39b6d77181_16-9-aspect-ratio_default_0.jpg" /></p><p>The Catalan pharmaceutical company Reig Jofre closed 2025 with a net profit of €4.99 million, 52% less than the previous year due to temporary production shutdowns and a 30% drop in antibiotic sales. In total, the majority family-owned group obtained revenues of €331.1 million, 2% less than in 2024. The year was marked by the company's industrial transformation. At the Toledo plant, planned shutdowns and the renovation of two antibiotic production lines were carried out in a context of recovering demand for oral antibiotics after the exceptional increases during the pandemic. Investments in the sterile area continued at the Barcelona plant. The company also <a href="https://en.ara.cat/economy/reig-jofre-increases-its-stake-in-leanbio-to-85_1_5580258.html">integrated Leanbio</a>and, therefore, Syna Therapeutics, which they had previously formed jointly.</p>]]></description>
      <dc:creator><![CDATA[Agustí Sala]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/reig-jofre-s-profit-falls-by-52-to-4-99-million-euros_1_5662672.html]]></guid>
      <pubDate><![CDATA[Fri, 27 Feb 2026 09:37:35 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/4516c048-8000-407f-ad9c-5f39b6d77181_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The Reig Jofre plant in Sant Joan Despí.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/4516c048-8000-407f-ad9c-5f39b6d77181_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The company earned 331.1 million, 2% less due to the drop in antibiotic sales caused by temporary shutdowns at its Toledo plant.]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Admiral quadruples its profits thanks to biological treatments]]></title>
      <link><![CDATA[https://en.ara.cat/economy/admiral-quadruples-its-profits-thanks-to-biological-treatments_1_5656687.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/26c1f3aa-79b1-4a57-8260-89d06a7a2764_16-9-aspect-ratio_default_0.jpg" /></p><p>Almirante continues to deepen its specialization in dermatology. This is reflected in 2025, as the company quadrupled its profits to €46.2 million thanks to its portfolio of biological treatments, compared to €10.1 million in 2024. Group sales exceeded €1 billion, specifically €1.108 billion, representing a 12.4% increase over the previous year. Total revenue was €1.114 billion, up 12.5%. Operating profit (EBITDA) reached €232.9 million, a 20.9% year-on-year increase, and the gross margin was 64.4%. The key driver of these results was dermatology sales in Europe, which increased by 25.6% to €608 million, the company reported in a statement on Monday.</p>]]></description>
      <dc:creator><![CDATA[ARA]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/admiral-quadruples-its-profits-thanks-to-biological-treatments_1_5656687.html]]></guid>
      <pubDate><![CDATA[Mon, 23 Feb 2026 09:03:41 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/26c1f3aa-79b1-4a57-8260-89d06a7a2764_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The facade of the headquarters of the Catalan pharmaceutical company Almirall on the Ronda General Mitre in Barcelona, in a file image.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/26c1f3aa-79b1-4a57-8260-89d06a7a2764_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The company closed 2025 with a profit of 46.2 million and a 12.4% increase in net sales, to 1,108 million.]]></subtitle>
    </item>
  </channel>
</rss>
